Po-Wei Lin

Mr. Lin is currently a researcher in the discovery research group of SanBio (Mountain View, CA), a company focusing on stem cell therapy and neuron regeneration medicine. Previously, Mr. Lin worked as research staff in Samsung Advanced Institute of Technology (SAIT, Korea), where he was actively involved in antibody new drug discovery and development. He also worked as Senior Scientist in cell line development group of Samsung Bioepis (Korea), where he attended several biosimilar projects. Mr. Lin is first and co-author of several international patents and publications, including the fields of new drug MoA study, combination treatment of oncologic targets, and angiogenesis. Mr. Lin received his MS degree in Zoology, molecular and cellular biology emphasis, from National Taiwan University. Due to his multicultural life experience, Mr. Lin speaks several languages, including Chinese, Taiwanese, English, Korean, and Japanese; therefore, he would like to help CBA bolster the interactions with its Korean and Japanese counterparts in the future. Mr. Lin volunteered his time for CBA in 2018 and helped the 2018 CBA conference proceeding composition and venue set up. Mr. Lin is CBA lifetime member. Mr. Lin enjoys reading, jogging, learning new things, making new friends, and playing the guitar.